Sodium phenylbutyrate is a synthetic derivative of phenylbutyric acid used as an alternative pathway for nitrogen excretion for patients with urea cycle disorders. It helps remove excess blood ammonia and prevents dangerous buildup in individuals with inborn errors of the urea cycle. The drug is administered orally or intravenously and is available as tablets or powder for solution preparations. It has been used to manage hyperammonemia caused by inherited genetic disorders characterized by enzyme deficiencies affecting the urea cycle.
The Global sodium phenylbutyrate market is estimated to be valued at US$ 2.22 Bn in 2024 and is expected to exhibit a CAGR of 18% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the sodium phenylbutyrate market are Halliburton Co., Hifi Engineering Inc., Silixa Ltd., Schlumberger Limited, Banweaver, Omnisens SA, Future Fibre Technologies Ltd., Baker Hughes, Inc., Qintiq Group PLC, and Fotech Solutions Ltd. The market offers opportunities for players to invest in new drug delivery systems and formulations to improve patient compliance. There is also scope for value-added services by developing companion diagnostics for better screening and management of urea cycle disorders. Major companies are expanding their geographical footprint in developing countries of Asia Pacific and Latin America through collaborations and acquisitions of regional players.
Market Drivers
The primary growth driver for the Sodium Phenylbutyrate Market Trends is rising incidences of urea cycle disorders such as carbamoyl phosphate synthetase deficiency, ornithine transcarbamylase deficiency, and citrullinemia. Increased screening programs and diagnostic capabilities have enabled higher detection rates of these rare genetic conditions. Additionally, rising health expenditures and demand for specialized disease management therapies further support market growth. Greater awareness amongst families with hereditary enzymatic disorder histories also contributes to volume sales.
PEST Analysis
Political: The regulations around the use and approval of new drug formulations can impact the sodium phenylbutyrate market. Changes in healthcare policies of different countries also affect the industry.
Economic: The overall economic growth and expenditure on healthcare impact the demand in the sodium phenylbutyrate market. Growing disposable income increases the accessibility of these drugs.
Social: Growing population and increasing prevalence of urea cycle disorders and hepatic encephalopathy is a major factor driving the market growth. Rising health awareness also increases the adoption of drugs for treating such conditions.
Technological: Advances in drug delivery methods help in improving the therapeutic efficacy and safety profile of sodium phenylbutyrate. New formulations with enhanced bioavailability are gaining popularity. Research is also ongoing to develop alternatives.
Geographical Regions of Concentration
North America dominates the global sodium phenylbutyrate market in terms of value, owing to the presence of major manufacturers in the region and higher adoption of orphan drugs for rare diseases. The US accounts for the largest share due to favorable regulatory environment and robust healthcare infrastructure. Europe is another major revenue generator due to rising government support for orphan drug development.
Fastest Growing Region
Asia Pacific is projected to witness the fastest growth over the forecast period in the global sodium phenylbutyrate market. This is attributed to growing healthcare expenditure, increasing patient pool of urea cycle disorders, and rising disposable income in developing countries such as India and China. Emerging economies in the region offer lucrative opportunities for market players.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it.